Description: Headquartered in Mountain View, California, IGM Biosciences is a biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.
Home Page: igmbio.com
IGMS Technical Analysis
325 East Middlefield Road
Mountain View,
CA
94043
United States
Phone:
650 965 7873
Officers
| Name | Title |
|---|---|
| Mr. Fred M. Schwarzer J.D. | CEO, Pres & Director |
| Dr. Lisa L. Decker Ph.D. | Chief Bus. Officer |
| Dr. Chris H. Takimoto FACP, M.D., Ph.D. | Chief Medical Officer |
| Mr. Misbah Tahir | Chief Financial Officer |
| Mr. Steven Weber | SVP, Corp. Controller & Principal Accounting Officer |
| Dr. Bruce A. Keyt | Chief Scientific Officer |
| Mr. Paul C. Graffagnino | VP of Legal Affairs |
| Ms. Suzette Tauber | Chief HR Officer |
| Dr. Shinyu Chen M.D., Ph.D. | Consultant |
| Dr. Angus M. Sinclair Ph.D. | Sr. VP of Immuno-Oncology |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.5826 |
| Price-to-Sales TTM: | 1136.7148 |
| IPO Date: | 2019-09-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 242 |